Department of Health and Human Services Awarded a Contract to FISHER SCIENTIFIC COMPANY L.L.C. for $10,157.64

Summary of Award

The US federal government has awarded a contract to Fisher Scientific Company L.L.C., a prominent entity in the bio-sciences sector. This particular contract, identified by the generated unique award ID "CONT_AWD_75N92025F00086_7529_GS07F161BA_4732," is categorized as a delivery order (type "C") and emphasizes the acquisition of reagents required for ongoing experimental projects at national laboratories. With a total obligation of $10,157.64, the contract's financial commitments reflect its scope and objectives.

### Contract Overview

The delivery order is precisely structured under the Federal Strategic Sourcing Initiative, driven by the General Services Administration and executed by the Federal Acquisition Service, with a PIID reference of "GS07F161BA." The contract, signed on April 10, 2025, reflects a government effort to leverage full and open competition for acquiring essential reagents. The process successfully attracted three offers, displaying the competitive nature of this procurement undertaken under the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The framework under which the award is executed involves comprehensive strategic planning. The competitive solicitation procedures categorized as "MAFO" (Multiple Award Fair Opportunity) highlight an environment where fair opportunity was given, aligning with federal standards for full and open competition. ### Recipient Details Fisher Scientific Company L.L.C., with a location in Pittsburgh, Pennsylvania, is not only a well-respected name but also a key player in the surgical appliance and supplies manufacturing sector. Their NAICS code, 339113, matches this specialization, positioning them as an industry leader in manufacturing medical, dental, and veterinary equipment and supplies, particularly drugs and biologicals. As a U.S.-owned corporate entity not tax-exempt and designated as a Limited Liability Corporation, Fisher Scientific is characterized by a robust corporate structure, supporting its extensive business operations throughout the country. ### Transactions and Financial Details The contract's financial dimensions are structured around a firm fixed price model, ensuring stability and predictability in financial commitments. Detailed within the record is the sole transaction recorded on the contract's signature date, aligned with the original agreement amount. This transaction, dated April 10, 2025, accounts for the entire obligated amount of $10,157.64, underscoring a straightforward funding pathway with no additional loans or subsidies involved. This clarity aligns well with Fisher Scientific's transparency in handling government contracts, further reinforcing the company's reputation. ### Agency and Awards Structure Tasked with this acquisition, the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, stands at the award's execution forefront. Renowned for its commitment to health advancements and research, the NIH's involvement denotes the award's significance in supporting ongoing experimental projects. The parent award sanctioning this transaction is nested within the General Services Administration's broader contract framework. The integration of Fisher Scientific within this complex structure denotes an effective partnership focused on advancing critical healthcare research. ### Performance and Execution The determined period of performance for this contract extends from April 10, 2025, to July 9, 2025. With no subaward distributions, Fisher Scientific is tasked with solely fulfilling the contract's requirements. The place of performance, Hanover Park, Illinois, further outlines the geographic diversity in project execution, highlighting Illinois's strategic importance for the NIH's operations. ### Executive Summary In summary, the awarded contract to Fisher Scientific Company L.L.C. represents a critical investment in biosciences research infrastructure. The targeted procurement of reagents is a cornerstone for ongoing experimental work, supported by a full and open competitive award process. Fisher Scientific leverages its significant presence within the manufacturing sector to fulfill this contract, dovetailing with its commitment to delivering cutting-edge scientific solutions. This contract signifies more than a mere procurement action; it is a strategic alignment between government agencies concentrated on advancing national health and research capabilities. The engagement of Fisher Scientific, a leader in medical supply manufacturing, reflects the federal government's strategic investment in sustaining and advancing experimental research needed to drive health and human services innovation.